Related Experiment Videos
[Regression of left ventricular hypertophy in the ECG during antihypertensive treatment: preliminary observations
Insights
Effective blood pressure reduction through combined drug treatment significantly reduced left ventricular hypertrophy (LVH) signs in patients with essential hypertension over four years.
Area of Science:
- Cardiology
- Hypertension Research
- Electrocardiography
Context:
- Essential hypertension is a common condition associated with cardiovascular complications.
- Left ventricular hypertrophy (LVH) is a significant indicator of cardiac damage in hypertensive patients.
- ECG is a primary diagnostic tool for identifying LVH.
Purpose:
- To evaluate the impact of long-term antihypertensive drug treatment on ECG-diagnosed left ventricular hypertrophy (LVH) in patients with essential hypertension.
- To assess the regression rate of LVH under effective blood pressure control.
Summary:
- A study followed 127 individuals with essential hypertension, identifying 36 with ECG signs of LVH.
- After two years of combined drug therapy (chlortalidone, reserpine, methyl-dopa, hydralazine) and effective blood pressure reduction, LVH persisted in 29 patients.
- Following four years of treatment, LVH was observed in only 15 patients, indicating a nearly 60% reduction in LVH prevalence. Body weight remained stable, attributing regression to drug efficacy.
Impact:
- Demonstrates that sustained, effective antihypertensive therapy can lead to significant regression of left ventricular hypertrophy.
- Highlights the potential for non-invasive methods like ECG to monitor treatment effectiveness in managing hypertensive heart disease.
- Provides evidence supporting the long-term benefits of combined drug regimens in mitigating cardiovascular remodeling in essential hypertension.
Abstract:
Typical signs of left ventricular hypertrophy (LVH) were present in the ECG of 36 (10 women, 26 men) of 127 persons with essential hypertension (46 women, 81 men). After a two-year course of combined drug treatment (chlortalidone, reserpine, methyl-dopa, hydralazine) with effective blood-pressure reduction LVH was still present in the ECG of 29, after a four-year course of only 15 among 36, i. e. a reduction in the presence of LVH of nearly 60%. Since the patients' body-weight remained unchanged during this period, the regression in ECG changes is ascribed to the effectiveness of the drug treatment.